[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:non-hodgkin-lymphoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":311,"states":337},"Non-Hodgkin Lymphoma",143,122,[8,16,23,29,36,42,48,54,60,66,72,78,84,90,96,102,108,114,120,127,133,139,145,151,157,163,169,175,181,187,193,198,204,210,216,222,228,234,240,246,252,258,264,270,276,282,288,294,300,305],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07532525","Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma",[12],"Phase 1","RECRUITING","2026-08-26T02:18:56.409949Z","2026-07-19T19:36:05.074801Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06090539","A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed\u002FRefractory Non-Hodgkin Lymphomas",[20],"Phase 1\u002FPhase 2","2026-08-26T02:17:52.450442Z","2026-07-05T05:32:16.741957Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT02917083","CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)",[12],"2026-08-26T02:17:13.277148Z","2026-05-29T15:36:40.172598Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT03258567","Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas",[33],"Phase 2","2026-08-26T02:16:35.654046Z","2026-05-05T02:43:29.390326Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT05618925","Study for Subjects With Relapsed\u002FRefractory Non- Hodgkin Lymphoma",[12],"2026-08-26T02:16:02.918558Z","2026-05-05T02:43:29.222602Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT06915246","A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma",[33],"2026-08-26T02:17:39.048487Z","2026-05-05T02:43:29.077122Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT05169515","A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and\u002For CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma",[12],"2026-08-03T02:58:35.674064Z","2026-05-05T02:43:28.970343Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT05892718","A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors",[12],"2026-08-26T02:18:12.612955Z","2026-05-05T02:43:28.547853Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT06504368","Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors",[12],"2026-08-26T02:16:01.910993Z","2026-05-05T02:43:28.121127Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":21,"content_modified":71},"NCT06876662","A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma or Non-Hodgkin Lymphoma",[70],"Phase 4","2026-05-05T02:43:27.845638Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT05312801","Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma",[12],"2026-08-26T02:19:06.150683Z","2026-05-05T02:43:27.676976Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT06104592","Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R\u002FR LBCL",[33],"2026-08-26T02:17:05.172421Z","2026-05-05T02:43:27.667369Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT06876649","A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib",[70],"2026-08-26T02:15:20.225313Z","2026-05-05T02:43:27.514528Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT07478848","Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas",[12],"2026-08-26T02:18:57.189473Z","2026-05-05T02:43:27.504670Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT07222631","SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas",[20],"2026-08-26T02:17:33.002248Z","2026-05-05T02:43:26.747555Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT04496349","A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R\u002FR T-PLL and NHL",[33],"2026-08-26T02:16:38.897933Z","2026-04-29T02:57:57.115952Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT05365659","IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas",[12],"2026-08-26T02:18:09.641312Z","2026-07-30T01:46:14.462340Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT07226843","A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers",[12],"2026-08-26T02:15:58.452248Z","2026-07-05T05:32:16.666342Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":125,"content_modified":126},"NCT07582432","A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma",[124],"Phase 3","2026-08-26T02:15:47.754948Z","2026-05-13T02:55:06.792854Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT06393738","A Study of ARV-393 in Relapsed\u002FRefractory Non-Hodgkin Lymphoma.",[12],"2026-08-26T02:17:36.611194Z","2026-05-05T02:43:29.734935Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":137,"content_modified":138},"NCT05909059","CAR T-cell Therapy in Patients With Renal Dysfunction",[33],"2026-08-26T02:16:42.787115Z","2026-05-05T02:43:29.640977Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":143,"content_modified":144},"NCT06550141","Emapalumab Prevention of CAR-T Cell Associated Toxicities",[33],"2026-08-26T02:19:24.527214Z","2026-05-05T02:43:29.284441Z",{"nct_id":146,"title":147,"phases":148,"status":13,"updated_at":149,"content_modified":150},"NCT07220993","Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells",[12],"2026-08-26T02:15:36.077529Z","2026-05-05T02:43:28.987867Z",{"nct_id":152,"title":153,"phases":154,"status":13,"updated_at":155,"content_modified":156},"NCT07188090","Mozobil for Autologous Hematopoietic Stem Cell Transplantation",[33],"2026-08-26T02:16:04.914942Z","2026-05-05T02:43:28.971071Z",{"nct_id":158,"title":159,"phases":160,"status":13,"updated_at":161,"content_modified":162},"NCT01853631","Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)",[12],"2026-08-26T02:19:30.857183Z","2026-05-05T02:43:28.649787Z",{"nct_id":164,"title":165,"phases":166,"status":13,"updated_at":167,"content_modified":168},"NCT06578624","Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors",[20],"2026-08-26T02:19:27.519777Z","2026-05-05T02:43:28.546807Z",{"nct_id":170,"title":171,"phases":172,"status":13,"updated_at":173,"content_modified":174},"NCT01555892","Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE",[12],"2026-08-26T02:16:36.513735Z","2026-05-05T02:43:28.315377Z",{"nct_id":176,"title":177,"phases":178,"status":13,"updated_at":179,"content_modified":180},"NCT05702853","Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed\u002FRefractory NHL, CLL\u002FSLL",[20],"2026-08-26T02:16:18.872924Z","2026-05-05T02:43:28.285448Z",{"nct_id":182,"title":183,"phases":184,"status":13,"updated_at":185,"content_modified":186},"NCT04664179","EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma",[12],"2026-08-26T02:19:19.162260Z","2026-05-05T02:43:27.322391Z",{"nct_id":188,"title":189,"phases":190,"status":13,"updated_at":191,"content_modified":192},"NCT05873712","Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome",[33],"2026-08-26T02:16:08.402952Z","2026-05-05T02:43:27.245708Z",{"nct_id":194,"title":195,"phases":196,"status":13,"updated_at":94,"content_modified":197},"NCT03081910","Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen",[12],"2026-05-05T02:43:26.923493Z",{"nct_id":199,"title":200,"phases":201,"status":13,"updated_at":202,"content_modified":203},"NCT06119685","IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers",[20],"2026-08-26T02:16:33.772093Z","2026-05-05T02:35:31.931545Z",{"nct_id":205,"title":206,"phases":207,"status":13,"updated_at":208,"content_modified":209},"NCT06223542","Studying TAK-243 in Patients With Advanced Cancer",[12],"2026-08-26T02:17:34.833510Z","2026-05-05T02:35:31.917344Z",{"nct_id":211,"title":212,"phases":213,"status":13,"updated_at":214,"content_modified":215},"NCT05645107","A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma",[124],"2026-08-26T02:18:27.904411Z","2026-05-05T02:35:31.872675Z",{"nct_id":217,"title":218,"phases":219,"status":13,"updated_at":220,"content_modified":221},"NCT05529069","Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients",[33],"2026-08-26T02:17:50.500039Z","2026-05-05T02:35:31.765634Z",{"nct_id":223,"title":224,"phases":225,"status":13,"updated_at":226,"content_modified":227},"NCT06227026","Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed\u002FRefractory CD19+ Malignancies",[12],"2026-08-26T02:15:11.740957Z","2026-04-29T02:57:57.116949Z",{"nct_id":229,"title":230,"phases":231,"status":13,"updated_at":232,"content_modified":233},"NCT06580002","Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial",[33],"2026-08-26T02:15:04.877798Z","2026-07-19T19:36:05.038415Z",{"nct_id":235,"title":236,"phases":237,"status":13,"updated_at":238,"content_modified":239},"NCT05442515","CD19\u002FCD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies",[20],"2026-08-26T02:18:21.216897Z","2026-07-05T05:32:16.802455Z",{"nct_id":241,"title":242,"phases":243,"status":13,"updated_at":244,"content_modified":245},"NCT07101328","A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )",[12],"2026-08-26T02:15:54.846520Z","2026-07-05T05:32:16.733199Z",{"nct_id":247,"title":248,"phases":249,"status":13,"updated_at":250,"content_modified":251},"NCT04545762","Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma",[12],"2026-08-26T02:18:03.638950Z","2026-07-05T03:45:20.448716Z",{"nct_id":253,"title":254,"phases":255,"status":13,"updated_at":256,"content_modified":257},"NCT04902443","Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV",[12],"2026-08-26T02:17:27.435233Z","2026-06-18T12:24:02.872345Z",{"nct_id":259,"title":260,"phases":261,"status":13,"updated_at":262,"content_modified":263},"NCT07566377","Cord Blood Transplantation in Children and Young Adults With Blood Cancer",[33],"2026-08-26T02:15:09.079045Z","2026-05-13T02:55:06.730274Z",{"nct_id":265,"title":266,"phases":267,"status":13,"updated_at":268,"content_modified":269},"NCT06801002","Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies",[12],"2026-08-26T02:19:10.436356Z","2026-05-05T02:43:29.672207Z",{"nct_id":271,"title":272,"phases":273,"status":13,"updated_at":274,"content_modified":275},"NCT04640987","Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback",[12],"2026-08-26T02:19:00.742020Z","2026-05-05T02:43:29.667798Z",{"nct_id":277,"title":278,"phases":279,"status":13,"updated_at":280,"content_modified":281},"NCT05260957","CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory\u002FRelapsed Aggressive Non-Hodgkin's Lymphoma (NHL).",[33],"2026-08-26T02:18:59.761994Z","2026-05-05T02:43:29.501361Z",{"nct_id":283,"title":284,"phases":285,"status":13,"updated_at":286,"content_modified":287},"NCT03223610","Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed\u002FRefractory B-cell Lymphoma",[20],"2026-08-26T02:17:15.156099Z","2026-05-05T02:43:29.367349Z",{"nct_id":289,"title":290,"phases":291,"status":13,"updated_at":292,"content_modified":293},"NCT07283822","Amping up With PemJAK",[33],"2026-08-26T02:15:03.757872Z","2026-05-05T02:43:29.349629Z",{"nct_id":295,"title":296,"phases":297,"status":13,"updated_at":298,"content_modified":299},"NCT02508038","Alpha\u002FBeta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors",[12],"2026-08-26T02:17:26.640202Z","2026-05-05T02:43:29.192915Z",{"nct_id":301,"title":302,"phases":303,"status":13,"updated_at":40,"content_modified":304},"NCT04068597","Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies",[20],"2026-05-05T02:43:29.159659Z",{"nct_id":306,"title":307,"phases":308,"status":13,"updated_at":309,"content_modified":310},"NCT05031897","Two Step Haplo With Radiation Conditioning",[33],"2026-08-26T02:16:32.589113Z","2026-05-05T02:43:29.158573Z",[312,316,320,323,327,331,334],{"biomarker":313,"count":314,"slug":315},"CD19 Gene",11,"cd19-gene",{"biomarker":317,"count":318,"slug":319},"HLA Complex",5,"hla-complex",{"biomarker":321,"count":318,"slug":322},"MS4A1 Gene","ms4a1-gene",{"biomarker":324,"count":325,"slug":326},"X-linked Lymphoproliferative Syndrome 1",4,"x-linked-lymphoproliferative-syndrome-1",{"biomarker":328,"count":329,"slug":330},"BCL6 Gene",3,"bcl6-gene",{"biomarker":332,"count":329,"slug":333},"BCR\u002FABL1 Fusion Gene","bcr-abl1-fusion-gene",{"biomarker":335,"count":329,"slug":336},"CD22 Gene","cd22-gene",[338,342,346,350,354,357,361,365,369,373,377,380,384,388,392,396,400,404,407,410,414,417,421,425],{"state":339,"count":340,"slug":341},"Texas",45,"texas",{"state":343,"count":344,"slug":345},"California",39,"california",{"state":347,"count":348,"slug":349},"New York",34,"new-york",{"state":351,"count":352,"slug":353},"Florida",27,"florida",{"state":355,"count":352,"slug":356},"Ohio","ohio",{"state":358,"count":359,"slug":360},"Maryland",23,"maryland",{"state":362,"count":363,"slug":364},"North Carolina",22,"north-carolina",{"state":366,"count":367,"slug":368},"Massachusetts",21,"massachusetts",{"state":370,"count":371,"slug":372},"Pennsylvania",20,"pennsylvania",{"state":374,"count":375,"slug":376},"Georgia",19,"georgia",{"state":378,"count":375,"slug":379},"Tennessee","tennessee",{"state":381,"count":382,"slug":383},"Wisconsin",18,"wisconsin",{"state":385,"count":386,"slug":387},"Washington",17,"washington",{"state":389,"count":390,"slug":391},"Minnesota",16,"minnesota",{"state":393,"count":394,"slug":395},"Michigan",15,"michigan",{"state":397,"count":398,"slug":399},"Arizona",14,"arizona",{"state":401,"count":402,"slug":403},"Colorado",13,"colorado",{"state":405,"count":402,"slug":406},"Illinois","illinois",{"state":408,"count":402,"slug":409},"Utah","utah",{"state":411,"count":412,"slug":413},"Missouri",12,"missouri",{"state":415,"count":314,"slug":416},"Oregon","oregon",{"state":418,"count":419,"slug":420},"New Jersey",10,"new-jersey",{"state":422,"count":423,"slug":424},"Indiana",8,"indiana",{"state":426,"count":423,"slug":427},"Kansas","kansas"]